Here's the gist, there are a few figures and further explanation...

Here's the gist, there are a few figures and further explanation in the announcement.

MMJ PhytoTech Limited (ASX:MMJ) (the “Company”) are pleased to announce that on 11 February 2016 the Company’s Israeli subsidiary, Phytotech Therapeutics Ltd, received very successful results from its Phase 1 clinical trial (Trial) being undertaken on two medicinal cannabis (MC) oral capsule formulations licensed exclusively from Yissum, the commercialisation arm of the Hebrew University of Jerusalem.

Phase 1 Clinical Trial Results

The results of the Trials are extremely positive with consistent results among all 14 completers (14/15 initiating test subjects).

The Trial yielded the following promising results;

•   Demonstrable safety and tolerability profile with no significant side effects;
  
  
•   Higher bioavailability of active compounds in comparison to GW Pharmaceuticals
  
  oromucosal spray – Sativex;
  
  
•   Very rapid onset; and
  
  
•   8 hours exposure time in the blood.